CUSIP: 62921N105
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
47,197,224
-
Share change
-
-824,342
-
Total reported value
-
$192,506,190
-
Put/Call ratio
-
0.76%
-
Price per share
-
$4.08
-
Number of holders
-
121
-
Value change
-
-$4,758,058
-
Number of buys
-
57
-
Number of sells
-
60
Quarterly Holders Quick Answers
What is CUSIP 62921N105?
CUSIP 62921N105 identifies NGM - NGM BIOPHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 62921N105:
Institutional Holders of NGM BIOPHARMACEUTICALS INC - COM (NGM) as of Q1 2023
As of 31 Mar 2023,
NGM BIOPHARMACEUTICALS INC - COM (NGM) was held by
121 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,197,224 shares.
The largest 10 holders included
Column Group LLC, EcoR1 Capital, LLC, BlackRock Inc., VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, Nuveen Asset Management, LLC, Euclidean Capital LLC, and JACOBS LEVY EQUITY MANAGEMENT, INC.
This page lists
121
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.